Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KB | Q9UBF8 | 4/20 | 0.36 |
| ▸ | NCS1 | P62166 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 5/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | RAF1 | P04049 | 2/20 | 0.32 |
| ▸ | DHODH | Q02127 | 1/20 | 0.32 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | POLQ | O75417 | 1/20 | 0.31 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.31 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18113856 | 0.89 | P2RY1 (0.38) | PI4KBNCS1ABL1DGAT1DHODH | |
| SCHEMBL20481613 | 0.84 | CFTR (0.35) | PI4KBNCS1HTTSMN1; SMN2 | |
| SCHEMBL18113798 | 0.82 | KDM4E (0.34) | PI4KBNCS1ABL1BRAFRAF1 | |
| SCHEMBL18113905 | 0.80 | RAF1 (0.38) | PI4KBABL1BRAFRAF1POLQ | |
| SCHEMBL18113881 | 0.80 | PI4KB (0.36) | PI4KBNCS1NPC1TP53HTT | |
| SCHEMBL20481494 | 0.80 | ADORA2A (0.46) | PI4KBNCS1 | |
| SCHEMBL18113801 | 0.80 | NCS1 (0.36) | PI4KBNCS1DHODHNPC1RAB9A | |
| SCHEMBL18113820 | 0.78 | P2RY1 (0.47) | HTTSMN1; SMN2POLQ | |
| SCHEMBL18113904 | 0.78 | POLQ (0.40) | PI4KBABL1POLQ | |
| SCHEMBL18113893 | 0.78 | NPC1 (0.38) | PI4KBABL1NPC1TP53HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180243298-A1 | TRPV3 MODULATORS | ABBVIE INC. | 2018-08-30 | — | — | US | claimed |
| WO-2016160938-A1 | N-(1,3-THIAZOL-2-YL)PYRIMIDINE-5-CARBOXAMIDES AS TRPV3 MODULATORS | ABBVIE INC. (US) | 2016-10-06 | — | — | WO | claimed |
| US-20180243298-A1 | TRPV3 MODULATORS | ABBVIE INC. | 2018-08-30 | — | — | US | disclosed |
| WO-2016160938-A1 | N-(1,3-THIAZOL-2-YL)PYRIMIDINE-5-CARBOXAMIDES AS TRPV3 MODULATORS | ABBVIE INC. (US) | 2016-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180243298-A1 | TRPV3 MODULATORS | TRPV3, TRPV1, TRPV2 | PI4KB 2233/4885NCS1 480/4885ABL1 4491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.